Dynamics of an HIV Model with Multiple Infection Stages and Treatment with Different Drug Classes

详细信息    查看全文

• 作者：Xia Wang ; Xinyu Song ; Sanyi Tang ; Libin Rong
• 关键词：Viral decay dynamics ; Multiple stages ; Antiretroviral therapy ; Integrase inhibitor ; Life cycle
• 刊名：Bulletin of Mathematical Biology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：78
• 期：2
• 页码：322-349
• 全文大小：1,615 KB
• 参考文献：Andrade A, Guedj J, Rosenkranz SL et al (2015) Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). AIDS 29(18):2419–2426CrossRef
  Andrade A, Rosenkranz SL, Cillo AR et al (2013) Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis 208(6):884–891CrossRef
  Browne CJ, Pilyugin SS (2012) Periodic multidrug therapy in a within-host virus model. Bull Math Biol 74:562–589CrossRef MathSciNet MATH
  Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T et al (2010) Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother 54:1047–1054CrossRef
  Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT et al (1981) Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305:1425–1431CrossRef
  Gallo RC, Sarinm PS, Gelmann EP, Robertguroff M, Richardson E et al (1983) Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220:865–867CrossRef
  Gumel AB, McCluskey CC, van den Driessche P (2006) Mathematical study of a staged-progression HIV model with imperfect vaccine. Bull Math Biol 68:2105–2128CrossRef MathSciNet MATH
  Gilmore JB, Kelleher AD, Cooper DA et al (2013) Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action. PLoS Comput Biol 9:e1002971CrossRef MathSciNet
  Hollingsworth T, Anderson R, Fraser C (2008) HIV-1 transmission, by stage of infection. J Infect Dis 198:687–693CrossRef
  Hyman JM, Li J (2005) The reproductive number for an HIV model with differential infectivity and staged progression. Linear Algebra Appl 398:101–116CrossRef MathSciNet MATH
  Hyman JM, Li J, Stanley EA (1999) The differential infectivity and staged progression models for the transmission of HIV. Math Biosci 155:77–109CrossRef MATH
  Huang G, Takeuchi Y, Ma W (2010) Lyapunov functionals for delay differential equations model of viral infections. SIAM J Appl Math 70(7):2693–2708CrossRef MathSciNet MATH
  Hale J, Verduyn Lunel SM (1993) Introduction to functional differential equations. Appl Math Sci, vol 99. Springer-Verlag, New York
  Lai X, Zou X (2014) Modelling HIV-1 virus dynamics with both virus-to-cell infection and cell-to-cell transmission. SIAM Appl Math 74:898–917CrossRef MathSciNet MATH
  Longini I, Clark W Jr, Haber M et al (1989) The stages of HIV infection: waiting times and infection transmission probabilities. Springer, Berlin Heidelberg
  Lloyd AL (2001) The dependence of viral parameter estimates on the assumed viral life cycle: limitations of studies of viral load data. Proc R Soc Lond B Biol Sci 268(1469):847–854CrossRef
  Markowitz M, Nguyen BY, Gotuzzo E et al (2007) Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. JAIDS 46:125–133
  Murray JM, Emery S, Kelleher AD et al (2007) Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21:2315–2321CrossRef
  Murray JM, Kelleher AD, Cooper DA (2011) Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals. J Virol 85:10798–10805CrossRef
  Nelson PW, Murray JD, Perelson AS (2000) A model of HIV-1 pathogenesis that includes an intracellular delay. Math Biosci 163:201–215CrossRef MathSciNet MATH
  Nelson PW, Perelson AS (2002) Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci 179:73–94CrossRef MathSciNet MATH
  Perelson AS, Nelson PW (1999) Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev 41:3–44CrossRef MathSciNet MATH
  Perelson AS et al (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188–191CrossRef
  Perelson AS, Ribeiro RM (2013) Modeling the within-host dynamics of HIV infection. BMC Biol 11:96–105CrossRef
  Rong L, Gilchrist MA, Feng Z et al (2007a) Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility. J Theor Biol 247:804–818CrossRef MathSciNet
  Rong L, Feng Z, Perelson AS (2007b) Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy. SIAM Appl Math 67:731–756CrossRef MathSciNet MATH
  Rong L, Feng Z, Perelson AS (2007c) Emergence of HIV-1 drug resistance during antiretroviral treatment. Bull Math Biol 69:2027–2060CrossRef MathSciNet MATH
  Rong L, Perelson AS (2009a) Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol 260:308–331CrossRef MathSciNet
  Rong L, Perelson AS (2009b) Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol 5(10):e1000533CrossRef MathSciNet
  Rong L, Perelson AS (2009c) Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci 217:77–87CrossRef MathSciNet MATH
  Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF (2008) Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci USA 105:4832–4837CrossRef
  Sedaghat AR, Siliciano RF, Wilke CO (2009) Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther 14:263–271
  Shen L, Peterson S, Sedaghat AR et al (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14:762–766CrossRef
  Vaidya NK, Rong L, Marconi VC et al (2010) Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load. PLoS Comput Biol 6(11):e1001012CrossRef MathSciNet
  van den Driessche P, Watmough J (2002) Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math Biosci 180:29–48CrossRef MathSciNet MATH
  von Kleist M, Menz S, Huisinga W (2010) Drug-class specific impact of antivirals on the reproductive capacity of HIV. PLoS Comput Biol 6:e1000720CrossRef
  Wodarz D, Nelson PW (2002) Mathematical models of HIV pathogenesis and treatment. BioEssays 24:1178–1187CrossRef
  Wang X, Tao Y (2008) Lyapunov function and global properties of virus dynamics with CTL immune response. Int J Biomath 1:443–448CrossRef MathSciNet MATH
  Wang X, Elaiw AM, Song X (2012) Global properties of a delayed HIV infection model with CTL immune response. Appl Math Comput 218:9405–9414CrossRef MathSciNet MATH
  Wang X, Liu S (2012) Global properties of a delayed SIR epidemic model with multiple parallel infectious stages. Math Biosci Eng 9:685–695CrossRef MathSciNet MATH
  Wang X, Liu S (2013) A class of delayed viral models with saturation infection rate and immune response. Math Method Appl Sci 36:125–142CrossRef MATH
  Wang X, Liu S, Rong L (2014) Permanence and extinction of a non-autonomous HIV-1 model with two time delays. Discrete Cont Dyn Syst B 19:1783–1800CrossRef MathSciNet MATH
  Wang S, Rong L (2014) Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy. J Theor Biol 360:137–148CrossRef
  Wang S, Hottz P, Schechter M, Rong L (2015) Modeling the slow CD4+ T cell decline in HIV-infected individuals. PLoS Comput Biol 11(12):e1004665CrossRef
  Wawer M, Gray R, Sewankambo N et al (2005) Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai. Uganda J Infect Dis 191:1403–1409CrossRef
  Wei X et al (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117–122CrossRef
  World Health Organization (2014) Global health observatory (GHO): HIV/AIDS. http://​www.​who.​int/​gho/​hiv/​en/​ . Accessed Dec 2014
  
• 作者单位：Xia Wang (1) (2)
  Xinyu Song (2)
  Sanyi Tang (1)
  Libin Rong (3)
  
  1. School of Mathematics and Information Sciences, Shaanxi Normal University, Xi’an, 710062, China
  2. College of Mathematics and Information Science, Xinyang Normal University, Xinyang, 464000, China
  3. Department of Mathematics and Statistics, and Center for Biomedical Research, Oakland University, Rochester, MI, 48309, USA
  
• 刊物类别：Mathematics and Statistics
• 刊物主题：Mathematics
  Mathematical Biology
  
• 出版者：Springer New York
• ISSN：1522-9602

文摘

Highly active antiretroviral therapy can effectively control HIV replication in infected individuals. Some clinical and modeling studies suggested that viral decay dynamics may depend on the inhibited stages of the viral replication cycle. In this paper, we develop a general mathematical model incorporating multiple infection stages and various drug classes that can interfere with specific stages of the viral life cycle. We derive the basic reproductive number and obtain the global stability results of steady states. Using several simple cases of the general model, we study the effect of various drug classes on the dynamics of HIV decay. When drugs are assumed to be 100 % effective, drugs acting later in the viral life cycle lead to a faster or more rapid decay in viremia. This is consistent with some patient and experimental data, and also agrees with previous modeling results. When drugs are not 100 % effective, the viral decay dynamics are more complicated. Without a second population of long-lived infected cells, the viral load decline can have two phases if drugs act at an intermediate stage of the viral replication cycle. The slopes of viral load decline depend on the drug effectiveness, the death rate of infected cells at different stages, and the transition rate of infected cells from one to the next stage. With a second population of long-lived infected cells, the viral load decline can have three distinct phases, consistent with the observation in patients receiving antiretroviral therapy containing the integrase inhibitor raltegravir. We also fit modeling prediction to patient data under efavirenz (a nonnucleoside reverse-transcriptase inhibitor) and raltegravir treatment. The first-phase viral load decline under raltegravir therapy is longer than that under efavirenz, resulting in a lower viral load at initiation of the second-phase decline in patients taking raltegravir. This explains why patients taking a raltegravir-based therapy were faster to achieve viral suppression than those taking an efavirenz-based therapy. Taken together, this work provides a quantitative and systematic comparison of the effect of different drug classes on HIV decay dynamics and can explain the viral load decline in HIV patients treated with raltegravir-containing regimens.